Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.
CAMP4 Therapeutics Corporation, founded in 2015 and based in Cambridge, Massachusetts, is a bioinformatics company dedicated to advancing gene regulation technology. The company has developed a 4-D gene circuitry platform that codifies the activation of the 24,000 genes in the human body into a set of combinatorial rules based on signaling pathways. This innovative approach allows CAMP4 to control gene production by utilizing the existing mechanisms that regulate gene expression within cells. By focusing on the fundamental causes of diseases, CAMP4 aims to expedite the drug development process, significantly reducing both the time and risk associated with bringing new treatments to patients.
Nomad Health, Inc. operates an online marketplace that enables users to find freelance and permanent clinical work in the United States. Its market place enables doctors to search for jobs by location, pay rate, medical facility, and more; and healthcare facilities to find doctors. The company was incorporated in 2015 and is based in New York, New York.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.
Tessa Therapeutics Pte Ltd. is a biotechnology company focused on developing innovative cancer immunotherapies, specifically targeting solid tumors. Founded in 2011 and based in Singapore, the company specializes in creating virus-specific T cells and CAR T cells aimed at treating lymphoma. By advancing these therapies, Tessa Therapeutics seeks to provide healthcare providers with effective options to improve the lives of cancer patients.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its IMPACT™ platform, Seismic Therapeutic aims to tackle key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This comprehensive approach facilitates the creation of optimized therapies that can reach patients more quickly. The company is developing a pipeline of innovative biologics targeting adaptive immune system dysregulation, with the goal of treating autoimmune diseases.
Dewpoint Therapeutics, Inc. is a biotech company focused on researching biomolecular condensates and their role in cellular function. Established in 2018 and based in Boston, Massachusetts, the company aims to develop innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women’s health, and virology. Dewpoint Therapeutics utilizes a novel drug platform that specifically targets biomolecular condensates to advance its therapeutic solutions.
Cardurion Pharmaceuticals, LLC operates as a biotechnology company. The company was incorporated in 2017 and is based in Boston, Massachusetts.
Sonrai Security delivers an enterprise identity and data governance platform for AWS, Azure, Google Cloud, and Kubernetes. The Sonrai Dig platform is built on a sophisticated graph that identifies and monitors every possible relationship between identities and data that exists inside an organization’s public cloud. Dig’s Governance Automation Engine automates workflow, remediation, and prevention capabilities across cloud and security teams to ensure end-to-end security.
The company was founded in 2017 and is headquartered in New York.
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.
Nomad Health, Inc. operates an online marketplace that enables users to find freelance and permanent clinical work in the United States. Its market place enables doctors to search for jobs by location, pay rate, medical facility, and more; and healthcare facilities to find doctors. The company was incorporated in 2015 and is based in New York, New York.
Jnana Therapeutics Inc. is a Boston-based company founded in 2016 that operates a drug discovery platform centered on solute carrier (SLC) transporters. The company focuses on key disease pathways related to immunometabolism, lysosomal function, and mucosal defense, targeting areas such as immuno-oncology, inflammatory disorders, and neurological diseases. By leveraging its innovative approach, Jnana Therapeutics aims to discover and develop transformative medicines that address significant medical needs and improve patient outcomes.
ByHeart, Inc. is an infant and baby nutrition company focused on developing products that support various aspects of children's health, including immune, microbiome, cognitive, and digestive health. Established in 2016 and headquartered in New York, the company operates with facilities in Pennsylvania. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative foods and formulas, prioritizing natural ingredients and small-batch production to ensure quality. The company's commitment to promoting healthy growth and providing peace of mind for parents distinguishes it in the infant nutrition market.
FloQast builds cloud-based software that helps manage accounting departments by centralizing the workflow, assigning tasks, maintaining supporting documentation and automating reconciliations.
OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.
Wellthy, Inc. is a family care concierge service based in New York, established in 2014. The company specializes in assisting individuals and families in managing the complexities of care for chronically ill, aging, or disabled loved ones. Wellthy connects families with dedicated Care Coordinators who help navigate the logistical and administrative tasks associated with caregiving. Their platform enables families to track appointments, organize tasks, store important documents, and maintain communication. Wellthy addresses various needs beyond medical care, including legal, financial, housing, and emotional support. The service is designed to alleviate the burden of caregiving by taking on tasks such as making calls, scheduling appointments, and managing paperwork. Additionally, Wellthy partners with employers to offer a compassionate and scalable solution to support families dealing with aging-related issues, childcare, special needs, and other ongoing care challenges.
CubicPV is a solar industry that relies on legacy technologies with inherent limitations. Conventional solar modules convert sunlight to electricity using a single light-absorbing material and are nearing an efficiency threshold.
Lyndra Therapeutics is a biotechnology company focused on developing ultra-long-acting oral medications designed to replace daily pill regimens. By providing sustained-release therapies that can be administered weekly or even monthly, the company aims to enhance medication adherence and improve health outcomes. Their innovative approach includes polypill strategies that consolidate multiple medications into a single dose, thereby increasing safety and efficacy while potentially reducing overall healthcare costs. Lyndra Therapeutics is actively developing treatments for a range of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric conditions, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Established in 2015 and headquartered in Watertown, Massachusetts, the company seeks to make a significant impact on global health through its advanced therapeutic solutions.
CAMP4 Therapeutics Corporation, founded in 2015 and based in Cambridge, Massachusetts, is a bioinformatics company dedicated to advancing gene regulation technology. The company has developed a 4-D gene circuitry platform that codifies the activation of the 24,000 genes in the human body into a set of combinatorial rules based on signaling pathways. This innovative approach allows CAMP4 to control gene production by utilizing the existing mechanisms that regulate gene expression within cells. By focusing on the fundamental causes of diseases, CAMP4 aims to expedite the drug development process, significantly reducing both the time and risk associated with bringing new treatments to patients.
Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases. The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital.
Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
PMI BioPharma Solutions is providing a comprehensive service offering to advance drug discovery, pharmaceutical development, and clinical manufacturing for the pharmaceutical and biotechnology industries. PMI BioPharma Solutions is uniquely positioned to support individual projects or to serve as an extension of its customers’ development teams. PMI BioPharma Solutions is planning to scale its manufacturing capabilities to support late-stage clinical and commercial liquid and lyophilized filling demand, to help support projects from clinical development to commercial launch.
Engine Biosciences is a biotechnology company focused on drug discovery through the application of machine learning to genomics. Based in San Francisco and Singapore, the company has developed a proprietary platform that integrates high-throughput laboratory experimentation with artificial intelligence algorithms to analyze complex biological networks. This approach generates unique data on gene interactions and provides biological insights validated through controlled experiments. By deciphering the intricacies of genetic codes, Engine Biosciences aims to accelerate and reduce the costs of research and development for new medical therapies. The platform supports various applications, including target discovery, drug repositioning, and precision medicine, and is utilized by both the company's internal teams and its partners across a range of disease indications. Founded in 2014, the team includes members from prestigious institutions such as MIT, Harvard, and the Mayo Clinic.
Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches.
Akili’s cognitive engine enables three separate clinical game versions for remote data-capture, with features designed for patient engagement. Its proprietary adaptive mechanics allow the software to automatically personalize to the patient’s ability level with no clinician input required.
Akili is based in Boston, Massachusetts.
PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.
Hummingbird Bioscience Pte. Ltd. is a biotechnology company based in Singapore, specializing in the development of antibody-based therapeutics for cancer. Founded in 2014, it leverages advances in systems biology and a proprietary rational antibody discovery platform to create innovative biotherapeutics. The company focuses on a diverse pipeline of drug candidates, which includes lead assets such as HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, both aimed at addressing significant unmet medical needs in oncology. Hummingbird Bioscience has established strategic collaborations with notable organizations such as Cancer Research UK and Amgen, and it has received a product development grant from the Cancer Prevention and Research Institute of Texas. The company's goal is to enhance treatment options for patients facing challenging cancer diagnoses through its cutting-edge research and development efforts.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Tectonic is a privately held biotechnology company that aims to transform the discovery of novel GPCR-targeted drugs and unlock the therapeutic utility the most challenging receptors in the class. Tectonic’s founders are at the forefront of scientific research in biochemistry and molecular pharmacology with an extensive track record of entrepreneurial achievement.
Cohere Health, Inc., founded in 2019 and headquartered in Boston, Massachusetts, develops a software platform aimed at enhancing collaboration among healthcare stakeholders. The company focuses on improving the patient journey by creating a user-friendly experience for patients, healthcare providers, and health plans. Its mission includes increasing the quality of care, reducing overall healthcare costs, and fostering transparency throughout the patient care process. By leveraging technology, Cohere Health seeks to address the complexities of healthcare delivery, ultimately benefiting all parties involved.
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.
Tausight, Inc. develops a software for reducing healthcare cyber incidents of patient data theft. It serves chief information officer of health care sector. Tausight was founded in 2018 and is based in Sudbury, Massachusetts with additional office in San Francisco, California.
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that leverage its proprietary XTEN half-life extension platform, XPAT technology for analyzing protease activity in tumor environments, and ProTIA, an immuno-oncology therapeutic. Amunix aims to harness the immune system to develop safe and effective therapies for patients with solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, establishing strategic partnerships with several prominent organizations in the industry. Founded in 2006 and based in Mountain View, California, Amunix continues to advance its pipeline of novel biologics, focusing on improving treatment outcomes for cancer patients.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Developed by spine specialists, the SpineZone Method relieves long-term back and neck injuries without resorting to invasive procedures
Armorblox, Inc., founded in 2017 and headquartered in Cupertino, California, specializes in data security solutions that focus on safeguarding the human layer of organizations. The company utilizes advanced techniques in machine learning and artificial intelligence to protect against identity-based attacks and prevent data loss. As a venture-backed startup, Armorblox aims to enhance cybersecurity measures for businesses through innovative technology.
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.
B2Gnow specializes in developing software solutions aimed at enhancing diversity management and compliance for corporations, contractors, institutions, and government sectors. Their turn-key, hosted software automates various processes, including data gathering, tracking, reporting, and vendor management. By streamlining these administrative functions, B2Gnow enables organizations to save 60%-80% of the time typically spent on clerical activities, allowing them to concentrate on achieving their diversity objectives more effectively. The company's solutions not only reduce operational costs but also improve the overall impact and reach of diversity initiatives.
Automotive Titling Company, LLC provides vehicle title and registration services for the automotive industry. It serves dealers, fleet managers, and financial companies. Automotive Titling Company, LLC was formerly known as Automotive Titling of Colorado, Inc. and changed its name to Automotive Titling Company, LLC in November 2020. The company was founded in 1972 and is based in Centennial, Colorado.
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.
Tectonic is a privately held biotechnology company that aims to transform the discovery of novel GPCR-targeted drugs and unlock the therapeutic utility the most challenging receptors in the class. Tectonic’s founders are at the forefront of scientific research in biochemistry and molecular pharmacology with an extensive track record of entrepreneurial achievement.
Sesh Therapy Incorporated is a mental health company that delivers online group support through its mobile application. Founded in 2020 and headquartered in San Francisco, California, Sesh provides a range of sessions led by qualified mental health professionals, making mental healthcare more accessible and affordable compared to traditional therapy appointments. The platform aims to connect individuals seeking support in a collaborative environment, enhancing the overall mental health experience.
Automotive Titling Company, LLC provides vehicle title and registration services for the automotive industry. It serves dealers, fleet managers, and financial companies. Automotive Titling Company, LLC was formerly known as Automotive Titling of Colorado, Inc. and changed its name to Automotive Titling Company, LLC in November 2020. The company was founded in 1972 and is based in Centennial, Colorado.
Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
The One Health Company is a social impact company that brings precision medicine, used in humans, to dogs with cancer.
It started by offering dogs with cancer access to cutting edge human clinical trials at no cost. Then, they created FidoCure directly for veterinarians and pet parents to offer treatment options to more dogs across the country. The company built partnerships with the world's top cancer researchers and a network of 111 of the best veterinary hospitals.
Primmune Therapeutics, Inc., a biotechnology company, develops small molecule orally administered toll-like receptor 7 (TLR7) agonist to stimulate innate immunity in cancer immunotherapy. It offers TLR7 agonist for systemic activation of innate immunity. The company’s TLR7 is an agonist for acute and chronic viral infection. The company was founded in 2017 and is based in San Diego, California.
Sonrai Security delivers an enterprise identity and data governance platform for AWS, Azure, Google Cloud, and Kubernetes. The Sonrai Dig platform is built on a sophisticated graph that identifies and monitors every possible relationship between identities and data that exists inside an organization’s public cloud. Dig’s Governance Automation Engine automates workflow, remediation, and prevention capabilities across cloud and security teams to ensure end-to-end security.
The company was founded in 2017 and is headquartered in New York.
Dewpoint Therapeutics, Inc. is a biotech company focused on researching biomolecular condensates and their role in cellular function. Established in 2018 and based in Boston, Massachusetts, the company aims to develop innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women’s health, and virology. Dewpoint Therapeutics utilizes a novel drug platform that specifically targets biomolecular condensates to advance its therapeutic solutions.
ARInsights, LLC develops cloud based analyst relationship management software solutions. The company offers a software as a service (SaaS) based platform, ARchitect, which provides relationship management and workflow modules for analyst relations. It also provides ARchitect event manager, ARchitect portal, ARchitect database, ARchitect Relationship Manager, ARchitect Emailer, ARchitect mobile application, ARchitect Reporting, ARchitect Analyst Grouping, and ARchitect Briefing Book tools and plug-ins. In addition, the company provides ServicePlus solutions for strategic planning, project support, administration, and operational assistance services. The company was founded in 2004 and is based in Sunny Isles Beach, Florida.
Neogene Therapeutics, Inc. develops T cell therapies to treat cancer. The company was incorporated in 2018 and is headquartered in New York, New York.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Private Equity Round in 2020
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.
It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarily affecting girls that enable clients with providing therapy for it.
Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Foresight is a technology-enabled psychiatry and therapy services company. We directly employ psychiatrists, therapists, psychiatric nurse practitioners to treat patients in our offices. Our team of software and biomedical engineers create technology alongside our providers to revolutionize the care we provide.
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.
ByHeart, Inc. is an infant and baby nutrition company focused on developing products that support various aspects of children's health, including immune, microbiome, cognitive, and digestive health. Established in 2016 and headquartered in New York, the company operates with facilities in Pennsylvania. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative foods and formulas, prioritizing natural ingredients and small-batch production to ensure quality. The company's commitment to promoting healthy growth and providing peace of mind for parents distinguishes it in the infant nutrition market.
Pandion Operations, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for autoimmune diseases. Its lead product candidate, PT101, is an engineered variant of interleukin-2 (IL-2) currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions. Other product candidates include PT627, a systemic PD-1 agonist in preclinical studies; PT001, a bifunctional molecule designed to achieve tissue-selective immunomodulation in the gastrointestinal tract; and PT002, which combines an IL-2 mutein with a tether module for similar localized effects. The company collaborates with Astellas Pharma Inc. to develop immunomodulators aimed at autoimmune diseases specifically affecting the pancreas. Headquartered in Watertown, Massachusetts, Pandion Operations seeks to create innovative therapies that can provide durable and tissue-specific treatment options for patients suffering from these conditions.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that leverage its proprietary XTEN half-life extension platform, XPAT technology for analyzing protease activity in tumor environments, and ProTIA, an immuno-oncology therapeutic. Amunix aims to harness the immune system to develop safe and effective therapies for patients with solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, establishing strategic partnerships with several prominent organizations in the industry. Founded in 2006 and based in Mountain View, California, Amunix continues to advance its pipeline of novel biologics, focusing on improving treatment outcomes for cancer patients.
Notarize, Inc. operates an online notary platform that allows individuals and businesses to have documents notarized remotely through live video calls with commissioned eNotaries. Founded in May 2015 and headquartered in Boston, Massachusetts, Notarize provides several services, including a general notary service, Notarize for Business for organizations and developers, and Notarize for Mortgage, which streamlines the closing process by connecting lenders, title companies, and borrowers online. The platform is accessible via iOS, Android, and web applications, making it convenient for users. Notarize also offers an electronic will service, enhancing its suite of digital legal solutions. The company focuses on identity verification to ensure secure transactions, thereby helping clients protect their business and maintain compliance with notarization requirements.
Montis Biosciences develops immune-oncology therapeutics targeting the intersection between vascular dysfunction and immune suppression to treat solid tumors. It creates a target screening and assay platform to develop targets modulating interactions between tumor endothelial cells and perivascular macrophages. The company was founded in 2020 and is based in Meise, Belgium.
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
Mesodyne's solution is a novel ultra-high energy density, multi-fuel, silent, compact power generator. Our generators convert fuel to electricity with heat and light as intermediaries: a small micro combustor heats a photonic crystal to incandescence and the resulting light is tailored to the bandgap of an infrared cell resulting in unprecedented high efficiencies.
Amagma Therapeutics is a biotechnology company that specializes in the discovery and development of antibody therapeutics against inflammatory diseases. Its technology overactive extracellular proteases trigger tissue damage that can sustain broad inflammatory responses.
The company was founded in 2019 and headquartered in Waltham, Massachusetts.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
FloQast builds cloud-based software that helps manage accounting departments by centralizing the workflow, assigning tasks, maintaining supporting documentation and automating reconciliations.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.
1366 Technologies Inc. specializes in the development, manufacturing, and supply of silicon wafers, specifically 3D direct wafers and silicon solar wafers. Founded in 2007 and headquartered in Bedford, Massachusetts, the company operates additional locations in Shanghai, China, and Mumbai, India. 1366 Technologies has formed strategic partnerships with Hanwha Q CELLS Malaysia Sdn. Bhd. and Hanwha Q CELLS Co., Ltd., enhancing its capabilities in the solar industry. The company leverages existing investments in cell and module technology, offering businesses a differentiated and sustainable product roadmap for solar energy solutions.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Allstacks is a predictive, curated Business Intelligence for Software Engineering Managers. It is the leading predictive forecasting and risk management solution for software development. We deliver business outcomes, not just metrics. It was founded by Hersh Tapadia and Jeremy Freeman in 2017 and is based in Raleigh, North Carolina.
Private Equity Round in 2019
Cardurion Pharmaceuticals, LLC operates as a biotechnology company. The company was incorporated in 2017 and is based in Boston, Massachusetts.
Recurly, Inc. develops and provides enterprise-class subscription management solutions to optimize and automate revenue growth for businesses worldwide. Its subscription management solution allows users to speed time-to-value, maximize revenue, boost developer productivity, gain actionable insights, and ensure security and compliance. The company provides subscription management solutions, deep payments expertise, and data-driven billing intelligence to optimize subscription revenue growth for businesses. Its subscription management and billing platform manage subscription revenues for companies in digital media, streaming, publishing, SaaS, consumer goods, and professional services industries. The company was incorporated in 2009 and is based in San Francisco, California. It has additional offices in Boulder, Colorado and New Orleans, Louisiana.
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.
Notarize, Inc. operates an online notary platform that allows individuals and businesses to have documents notarized remotely through live video calls with commissioned eNotaries. Founded in May 2015 and headquartered in Boston, Massachusetts, Notarize provides several services, including a general notary service, Notarize for Business for organizations and developers, and Notarize for Mortgage, which streamlines the closing process by connecting lenders, title companies, and borrowers online. The platform is accessible via iOS, Android, and web applications, making it convenient for users. Notarize also offers an electronic will service, enhancing its suite of digital legal solutions. The company focuses on identity verification to ensure secure transactions, thereby helping clients protect their business and maintain compliance with notarization requirements.
Simon Data is the enterprise Customer Data Platform (CDP) that empowers brands to deliver data-driven, personalized customer experiences anywhere.The platform leverages enterprise-scale big data and machine learning to power customer communications in any channel. Simon’s unique approach allows brands to develop and deliver incredible personalization capabilities without needing to build and maintain massive bespoke data infrastructure. At Simon, our goal is to improve and optimize customer experiences by making the entire process, experimentation through analysis, a data-driven one.
Nomad Health, Inc. operates an online marketplace that enables users to find freelance and permanent clinical work in the United States. Its market place enables doctors to search for jobs by location, pay rate, medical facility, and more; and healthcare facilities to find doctors. The company was incorporated in 2015 and is based in New York, New York.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.
It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.